10X Genomics

  • TickerTXG
  • ISINUS88025U1097
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
 PRESS RELEASE
TXG 10X GENOMICS (Health Care)

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice. The agreemen...

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

 PRESS RELEASE
TXG 10X GENOMICS (Health Care)

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice. The agreemen...

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

 PRESS RELEASE
TXG 10X GENOMICS (Health Care)

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice. The agreemen...

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

 PRESS RELEASE
TXG 10X GENOMICS (Health Care)

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringement claims with prejudice. The agreemen...

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

TXG 10X GENOMICS (Health Care)

10X GENOMICS INCO. upgrades to Neutral based on its reduced risk expos...

The independent financial analyst theScreener just revised the risk rating of 10X GENOMICS INCO. (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 2 out of 4 stars. Its market behaviour, however, has improved and can be qualified as moderately risky. theScreener believes that the improved risk assessment offsets the loss of a star and merits an overall rating upgrade to Neutral. As of the analysis date July 9, 2021, the closing price was USD 190.41 and its expected value was estimated at USD 187.22.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch